The Cooper Companies, Inc. (NASDAQ:COO) Shares Sold by Cresset Asset Management LLC

Cresset Asset Management LLC cut its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 84.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,902 shares of the medical device company's stock after selling 21,575 shares during the quarter. Cresset Asset Management LLC's holdings in Cooper Companies were worth $359,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in Cooper Companies during the 4th quarter valued at about $691,000. Highland Capital Management LLC purchased a new position in Cooper Companies during the 4th quarter valued at about $4,004,000. Caprock Group LLC purchased a new position in Cooper Companies during the 4th quarter valued at about $282,000. Entropy Technologies LP purchased a new position in Cooper Companies during the 4th quarter valued at about $248,000. Finally, Lecap Asset Management Ltd. boosted its holdings in Cooper Companies by 33.1% during the 4th quarter. Lecap Asset Management Ltd. now owns 11,955 shares of the medical device company's stock valued at $1,099,000 after acquiring an additional 2,974 shares during the period. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on COO. Robert W. Baird lowered their target price on Cooper Companies from $117.00 to $107.00 and set an "outperform" rating for the company in a report on Friday, March 7th. JPMorgan Chase & Co. reduced their price target on Cooper Companies from $120.00 to $110.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Stifel Nicolaus reduced their price target on Cooper Companies from $115.00 to $105.00 and set a "buy" rating on the stock in a research report on Friday, March 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Cooper Companies in a research report on Friday, March 7th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $115.00 price target (down previously from $120.00) on shares of Cooper Companies in a research report on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $110.25.

Cooper Companies Stock Up 1.8%

Shares of NASDAQ COO traded up $1.47 during midday trading on Friday, hitting $82.92. 1,519,674 shares of the company's stock were exchanged, compared to its average volume of 1,471,543. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The Cooper Companies, Inc. has a twelve month low of $69.81 and a twelve month high of $112.38. The company has a market cap of $16.58 billion, a PE ratio of 42.52, a P/E/G ratio of 2.25 and a beta of 1.08. The firm's fifty day simple moving average is $80.19 and its 200-day simple moving average is $90.10.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business had revenue of $964.70 million for the quarter, compared to analyst estimates of $981.25 million. Research analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.